PeproMene Bio

PeproMene Bio, Inc., founded in Irvine, CA, is a clinical-stage biotech company focused on developing innovative immune-oncology therapies. Their core mission is to improve the lives of patients with cancer and immune disorders through novel treatments. The company's flagship product is the BAFF-R CAR-T therapy, which targets the B-cell Activating Factor Receptor (BAFF-R) using a novel antibody. This therapy aims to provide new hope for patients with challenging oncological and immunological conditions.

Notable figures associated with PeproMene Bio include leading scientists and industry experts in the field of immunotherapy. The company has garnered attention from private investors who support its pioneering research. Key achievements include advancing their BAFF-R CAR-T therapy to clinical stages, demonstrating promising potential in preclinical studies. PeproMene Bio's impact lies in its commitment to harnessing cutting-edge science to develop therapies that could significantly alter the treatment landscape for cancer and immune disorders.